Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition."
- None.
- None.
Insights
The issuance of U.S. patent # 11,898,184 for Impact Biomedical's Laetose™ technology represents a significant milestone in the company's intellectual property portfolio. The patented low glycemic sugar composition addresses a growing consumer demand for healthier food alternatives that can also play a role in managing chronic inflammatory diseases. The potential reduction of caloric intake and glycemic index in foods is a key factor in the fight against obesity and diabetes, conditions that are prevalent and on the rise globally.
By targeting the $35 billion U.S. inflammatory disease treatment market and the $30 billion (and growing) U.S. diabetes treatment market, Impact Biomedical positions itself at the intersection of healthcare and food industries. The innovation could disrupt the $12 billion U.S. refined sugar production market, offering a healthier alternative that mitigates the inflammatory response typically associated with sugar consumption. The long-term patent protection until 2037 provides a competitive edge and ample time for market penetration and return on investment.
However, the road from patent to product is often long and filled with regulatory hurdles. The company's strategy to seek licensing and development partners is crucial for commercialization. The success of Laetose™ will depend on the effectiveness of these partnerships, market acceptance and the ability to scale production while maintaining product efficacy.
Impact Biomedical's announcement concerning the newly issued patent for Laetose™ technology could have positive implications for its financial performance and that of its significant investor, DSS Inc. The patented technology's potential to cater to multiple large and growing markets—such as those for inflammatory disease treatment and diabetes management—suggests a substantial opportunity for revenue generation through licensing agreements, partnerships and product sales.
Investors should monitor the company's progress in securing partnerships and navigating the regulatory environment, as these will be critical factors influencing the timeline and extent of revenue growth. Additionally, the protection granted by the patent until 2037 offers a long-term competitive advantage that could result in sustained revenue streams if the technology is successfully commercialized. The impact on the stock market will be contingent on the company's execution of its go-to-market strategy and its ability to leverage this intellectual property effectively.
The Laetose™ technology's potential to inhibit tumor necrosis factor alpha (TNF-α) signals a noteworthy advancement in the treatment of chronic inflammatory diseases. TNF-α is a cytokine that plays a significant role in systemic inflammation and is implicated in a variety of diseases, including rheumatoid arthritis, psoriasis and Crohn's disease. The novel combination of sugars and myo-inositol in the patented formulation could offer a new approach to managing these conditions, which may be less invasive and have fewer side effects compared to current TNF-α inhibitors.
From a medical research perspective, the dual-action approach of Laetose™ in addressing both the inflammatory and metabolic responses to sugar intake is particularly innovative. The potential therapeutic applications of this technology could extend beyond the current scope, pending further clinical research. The efficacy and safety of the Laetose™ composition in a clinical setting will be critical to its success and acceptance in the medical community.
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled "Low Glycemic Sugar Composition" developed within this platform.
The Laetose™ technology demonstrates compelling potential in reducing caloric intake and glycemic index in foods, while also inhibiting tumor necrosis factor alpha (TNF-α), a cytokine associated with inflammatory chronic diseases.
The patented formulation is a novel combination of one or more sugars and myo-inositol, with potential to inhibit the inflammatory and metabolic response of sugar alone. This marks the first Laetose™ patent issued in the U.S., emphasizing IBIO’s commitment to discovering, developing, and patenting unique technologies to address unmet needs in human healthcare. The term of this US patent will expire in 2037.
The patented Laetose™ composition consists of an effective amount of sugar and myo-inositol, with potential applications in therapeutic administration to reduce or limit inflammatory or metabolic diseases (e.g., diabetes). The composition mitigates a TNF-α response to the sugar.
Potential Applications and Market Impact:
- US Inflammatory Disease Treatment Market: Estimated at
$35B (source: Precedence Research 2022) - US Diabetes Treatment Market: Currently at
$30B and projected to grow to$61B by 2028 (source: GlobeNewswire 2022) - US Refined Sugar Production Market: Valued at
$12B and expected to grow to$26B by 2028 (source: Knowledge Sourcing Intelligence)
Impact Biomedical CEO Frank D. Heuszel commented, “This is another demonstration of our commitment to address critical unmet needs in human healthcare. We are accelerating discussions with potential licensing and development partners to move Laetose™ rapidly towards the market in the US and other countries worldwide.”
About Impact Biomedical, Inc.: Impact Biomedical Inc. (“IBIO”) discovers, confirms, and patents unique science and technologies resulting in new offerings in human healthcare and wellness. IBIO works closely with licensing, co-development, joint ventures, and other relationships to bring these offerings to market. For more information, visit Impact Biomedical, Inc.
About DSS, Inc.: DSS is a multinational company operating businesses within four diversified market sectors. For more information on DSS, visit DSS World.
Safe Harbor Disclosure: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Investor Relations and Media Contact:
Contact:
DSS Inc. Investor Relations
+1 (585) 565-2422
FAQ
What is the U.S. patent number for the Laetose™ technology platform?
What is the potential application of the Laetose™ composition?
What is the estimated value of the US Inflammatory Disease Treatment Market?
Who is the CEO of Impact Biomedical Inc.?
What is the ticker symbol for DSS Inc.?
